BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 26921922)

  • 1. Role of the RANK/RANKL pathway in breast cancer.
    Kiesel L; Kohl A
    Maturitas; 2016 Apr; 86():10-6. PubMed ID: 26921922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives.
    Infante M; Fabi A; Cognetti F; Gorini S; Caprio M; Fabbri A
    J Exp Clin Cancer Res; 2019 Jan; 38(1):12. PubMed ID: 30621730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis.
    Dougall WC
    Clin Cancer Res; 2012 Jan; 18(2):326-35. PubMed ID: 22031096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can we prevent BRCA1-associated breast cancer by RANKL inhibition?
    Kotsopoulos J; Singer C; Narod SA
    Breast Cancer Res Treat; 2017 Jan; 161(1):11-16. PubMed ID: 27783278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The anti-tumor effect of RANKL inhibition in malignant solid tumors - A systematic review.
    de Groot AF; Appelman-Dijkstra NM; van der Burg SH; Kroep JR
    Cancer Treat Rev; 2018 Jan; 62():18-28. PubMed ID: 29154022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers.
    Nolan E; Vaillant F; Branstetter D; Pal B; Giner G; Whitehead L; Lok SW; Mann GB; ; Rohrbach K; Huang LY; Soriano R; Smyth GK; Dougall WC; Visvader JE; Lindeman GJ
    Nat Med; 2016 Aug; 22(8):933-9. PubMed ID: 27322743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RANKL/RANK: from bone loss to the prevention of breast cancer.
    Sigl V; Jones LP; Penninger JM
    Open Biol; 2016 Nov; 6(11):. PubMed ID: 27881737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Updates on the role of receptor activator of nuclear factor κB/receptor activator of nuclear factor κB ligand/osteoprotegerin pathway in breast cancer risk and treatment.
    Bayer CM; Beckmann MW; Fasching PA
    Curr Opin Obstet Gynecol; 2017 Feb; 29(1):4-11. PubMed ID: 28002265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Denosumab for the treatment of bone metastases in advanced breast cancer.
    Casas A; Llombart A; Martín M
    Breast; 2013 Oct; 22(5):585-92. PubMed ID: 23759273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting RANKL in breast cancer: bone metastasis and beyond.
    Azim H; Azim HA
    Expert Rev Anticancer Ther; 2013 Feb; 13(2):195-201. PubMed ID: 23406560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RANKL inhibition: a promising novel strategy for breast cancer treatment.
    González-Suárez E
    Clin Transl Oncol; 2011 Apr; 13(4):222-8. PubMed ID: 21493182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells.
    Cuyàs E; Corominas-Faja B; Martín MM; Martin-Castillo B; Lupu R; Brunet J; Bosch-Barrera J; Menendez JA
    Oncotarget; 2017 May; 8(21):35019-35032. PubMed ID: 28388533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis.
    Gonzalez-Suarez E; Jacob AP; Jones J; Miller R; Roudier-Meyer MP; Erwert R; Pinkas J; Branstetter D; Dougall WC
    Nature; 2010 Nov; 468(7320):103-7. PubMed ID: 20881963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RANK/RANKL signaling inhibition may improve the effectiveness of checkpoint blockade in cancer treatment.
    van Dam PA; Verhoeven Y; Trinh XB; Wouters A; Lardon F; Prenen H; Smits E; Baldewijns M; Lammens M
    Crit Rev Oncol Hematol; 2019 Jan; 133():85-91. PubMed ID: 30661662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progestogens and risk of breast cancer: a link between bone and breast?
    González Ricarte M; de Castro Pérez A; Tarín JJ; Cano A
    Gynecol Endocrinol; 2016; 32(1):6-8. PubMed ID: 26299383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Denosumab: RANKL inhibition in the management of bone loss.
    Hamdy NA
    Drugs Today (Barc); 2008 Jan; 44(1):7-21. PubMed ID: 18301800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell-based assay strategy for identification of motif-specific RANK signaling pathway inhibitors.
    Chen T; Feng X
    Assay Drug Dev Technol; 2006 Aug; 4(4):473-82. PubMed ID: 16945019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of receptor activator of nuclear factor kappa-B as a poor prognostic marker in breast cancer.
    Park HS; Lee A; Chae BJ; Bae JS; Song BJ; Jung SS
    J Surg Oncol; 2014 Dec; 110(7):807-12. PubMed ID: 25111682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RANKL/RANK - from bone physiology to breast cancer.
    Sigl V; Penninger JM
    Cytokine Growth Factor Rev; 2014 Apr; 25(2):205-14. PubMed ID: 24486161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Roadmap of RANKL/RANK Pathway in Cancer.
    Casimiro S; Vilhais G; Gomes I; Costa L
    Cells; 2021 Aug; 10(8):. PubMed ID: 34440747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.